ALK and lung carcinoma: YAP also confers resistance to chemotherapeutic agents such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), and anaplastic lymphoma kinase (ALK) inhibitors in lung cancer [14,15,16].